Autolus Therapeutics Files 8-K on Shareholder Votes
Ticker: AUTL · Form: 8-K · Filed: 2024-06-28T00:00:00.000Z
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: AUTL
TL;DR
Autolus had a shareholder vote on 6/28. Details TBD.
AI Summary
Autolus Therapeutics plc filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions, but it serves as an official notification of such events.
Why It Matters
This filing indicates that Autolus Therapeutics plc has held or is holding a shareholder meeting where important corporate decisions are being voted upon, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is a procedural notification of a shareholder vote and does not disclose any new material financial or operational risks.
Key Players & Entities
- Autolus Therapeutics plc (company) — Registrant
- June 28, 2024 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Autolus Therapeutics plc's security holders on June 28, 2024?
The 8-K filing states that the purpose of the report is to disclose "Submission of Matters to a Vote of Security Holders" but does not detail the specific resolutions or proposals voted upon.
Where is Autolus Therapeutics plc's principal executive office located?
Autolus Therapeutics plc's principal executive offices are located at The Mediaworks, 191 Wood Lane, London W12 7FP, United Kingdom.
What is the SEC file number for Autolus Therapeutics plc?
The SEC file number for Autolus Therapeutics plc is 001-38547.
When was Autolus Therapeutics plc incorporated or organized?
Autolus Therapeutics plc was incorporated or organized in England and Wales.
What is the standard industrial classification for Autolus Therapeutics plc?
The standard industrial classification for Autolus Therapeutics plc is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
From the Filing
0001730463-24-000076.txt : 20240628 0001730463-24-000076.hdr.sgml : 20240628 20240628160414 ACCESSION NUMBER: 0001730463-24-000076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240628 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240628 DATE AS OF CHANGE: 20240628 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 241085584 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 autl-20240628.htm 8-K autl-20240628 0001730463 FALSE 0001730463 2024-06-28 2024-06-28 0001730463 sic:Z8880 2024-06-28 2024-06-28 0001730463 us-gaap:CommonClassAMember 2024-06-28 2024-06-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) (44) 20 3829 6230 (Registrant's telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share* * The Nasdaq Stock Market LLC * * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. a